Abstract Library

#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Duan H

Authors: Duan H, Ninatti G, Girod B, Ferri V, Guja K,

Keywords: NET, PRRT, ORR, PFS,

#2890 Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)

Introduction: Peptide receptor radionuclide therapy (PRRT) is an encouraging systemic treatment for neuroendocrine tumors (NET). PRRT is generally safe and possesses little side effects but little is known about liver toxicity.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Duan H

Authors: Duan H, Girod B, Ninatti G, Ferri V, Kunz P,

Keywords: NET, PRRT, Toxicity,

#2788 Favourable Outcome in Patients with Metastatic Pheochromocytomas and Paragangliomas Treated with 177Lu-DOTATATE

Introduction: There is limited previous data on Peptide receptor radiotherapy (PRRT) in pheochromocytoma (PCC) and paraganglioma (PGL).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Vyakaranam A

Authors: Vyakaranam A, Crona J, Thiis-Evensen E, Hellman P, Norlén O,

Keywords: PRRT, 177Lu-DOTATATE, Pheochromocytoma, Paraganglioma,

#2230 Does Somatostatin Receptor (SSR) Positive Tumor Volume Determined on Ga68 DOTANOC PET/CT in Patients with Paraganglioma (PGL)/Pheochromocytoma(PCC) Correlate with Biomarkers? An Explorative Study

Introduction: SSR PET/CT is used in workup of pts with PCC/ PGL. Correlation of tumour burden on PET & biomarkers 24 hr Urine Metanephrines (UMET), normetanephrine (UNMET), UMET:creatinine ratio (MET:Crea),UNMET:creatinine (UNMET:crea) & Chromogranin A (CGA) has not been done.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Steyn R

Authors: Steyn R, Prasad V,

Keywords: 68Ga DOTANOC PET CT, PGL, PCC,

#2218 More than Rare Pheochromocytomas: Bilateral and Hemorrhagic, Giant and Metastatic

Introduction: Pheochromocytomas (PCC) are rare neuroendocrine tumors. These catecholamine-secreting tumors, with an average size of 4.9cm, are multiple in 10% of cases. About 10% are malignant but distant metastases are rare. Non-traumatic adrenal hemorrhage is an unusual potentially fatal event seen in PCC.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Peralta Ferreira M

Authors: Peralta Ferreira M, Sousa Fernandes M, Roque R, Matos C, Strecht J,

Keywords: pheochromocytoma, giant, hemorrhagic, metastatic, bilateral,